Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 2-11

  Sands, Bruce E ^a   Kozarek, Richard ^b   Spainhour, Jack ^c   Barish, Charles F ^d   Becker, Scott ^e   Goldberg, Lawrence ^f   Katz, Seymour ^g   Goldblum, Ronald ^h   Harrigan, Rena ^h   Hilton, Eborah ^h   Hanauer, Stephen B ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c Internal Medicine Associates   (United States)

^d WAKE RESEARCH ASSOCIATES   (United States)

^e Austin Gastroenterology   (United States)

^f Borland Groover Clinic   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ELAN PHARMACEUTICALS   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

Combination therapy; Crohn's disease; Infliximab; Natalizumab; Randomized controlled trial

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; STEROID;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE MARKER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTEROCUTANEOUS FISTULA; FATIGUE; FEMALE; FEVER; HEADACHE; HOT FLUSH; HUMAN; INFLAMMATION; INSOMNIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPPORTUNISTIC INFECTION; PHARYNGITIS; PLEURISY; PRIORITY JOURNAL; PROCTALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; THORAX DISEASE; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTEGRIN ALPHA4; MALE; QUALITY OF LIFE; SERUM ALBUMIN;

EID: 33846184129     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20014     Document Type: Article

References (18)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
4. Sands E, van Deventer JH, Bernstein C, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
5. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
6. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372-2382.
7. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Eng J Med. 2003;348:24-32.
8. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
9. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368.
10. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-374.
11. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-381.
12. Yousry TA, Major E, Ryschkewitsch C, et al. evaluation for progressive multifocal leukoencephalopathy in natalizumab treated patients. N Engl J Med, in press.
13. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287-296.
15. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75-79.
16. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1989.
17. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10:333-338.
18. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.